DIRS.INFO The most relevant business & tech news

☆ Op-ed: Here’s why a sale of Bausch + Lomb could lead to a windfall for Bausch Health investors
▼ + stars: | 2024-09-17 | by ( Kenneth Squire | ) www.cnbc.com time to read: +7 min

Bausch + Lomb parent company Bausch Health is spinning off the eye-care company with an upcoming IPO which will list on the New York Stock Exchange and TSX with the ticker symbol “BLCO”. This would greatly benefit BLCO stockholders, of which Bausch Health is the largest. As an 88% owner of BLCO, Bausch Health's value derived from such a sale would be $12.32 billion. Adding the value of the proceeds from BLCO sale, the Xifaxan cash flows and RemainCo yields a total value of $25.93 billion for Bausch Health. After subtracting 100% of the Bausch Health debt, that would yield an equity value of $10.49 billion or $28.19 per share.

Persons: Bausch, Scott Olson, Richard Mulligan, John Paulson, Brett Icahn, Steven Miller, Carl Icahn, BLCO, Goldman Sachs, Bausch Health's, Peers, InMode, Takeda, Gary Hu, Brent Saunders, Ken Squire Organizations: Bausch Health, New York Stock Exchange, TSX, U.S . Securities, Exchange, Financial Times, Cooper Companies, BLCO, Products, Takeda Pharmaceuticals, Ironwood Pharmaceuticals, Health, 13D Locations: CHICAGO , ILLINOIS, Chicago , Illinois, BLCO

Taking a high dose of ADHD drugs is linked to more than five times greater risk of developing psychosis or mania, according to a new study published Thursday in the American Journal of Psychiatry. The research is among the first to find a relationship between escalating doses of the drugs — amphetamines, in particular — and a greater likelihood of psychotic symptoms. The drugs include Adderall, Vyvanse and generic amphetamines, such as dextroamphetamine. The medium dosage — 20 mg to 40 mg of Adderall, 50 mg to 100 mg of Vyvanse or 15 mg to 30 mg of dextroamphetamine — was linked to a 3.5 times higher risk. There was no increased risk of psychosis with another ADHD drug, Ritalin, which isn’t an amphetamine.

Persons: it’s, ”, Jacob Ballon, hadn’t, Will Cronenwett, ” Cronenwett, Vyvanse, Takeda, Lauren Moran, Brigham, “, ” Moran, Moran, Cronenwett, ” Ballon, they’re Organizations: American, of Psychiatry, Stanford Medicine, Northwestern Medicine, Psychiatry, NBC News, Takeda Pharmaceuticals, . Food, Drug Administration, FDA, Pharmaceuticals, McLean Hospital, Mass Locations: United States, U.S, Boston

☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
▼ + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.

Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive

☆ 2023 was a tough year for us, but we expect a rebound in 2024: Takeda Pharmaceuticals CEO
▼ + stars: | 2024-02-02 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email2023 was a tough year for us, but we expect a rebound in 2024: Takeda Pharmaceuticals CEOChristophe Weber, CEO of Takeda Pharmaceuticals says product pipeline was very positive in the last quarter and shares his business outlook for 2024.

Persons: Christophe Weber, Takeda Organizations: Takeda, Takeda Pharmaceuticals

☆ Pharma giants are hiking prices on over 500 drugs for 2024, report says
▼ + stars: | 2024-01-02 | by ( Rebecca Rommen | ) www.businessinsider.com time to read: +1 min

Read previewPharmaceutical giants Pfizer, Sanofi, and Takeda Pharmaceutical are due to raise prices on more than 500 drugs in the US from January, according to the Reuters news agency. This story is available exclusively to Business Insider subscribers. It comes as the pharmaceutical sector prepares for the Biden Administration's release of discounted prices for 10 high-cost drugs in September. AdvertisementFurther in the future, the Biden administration's Inflation Reduction Act includes new provisions to allow the government's Medicaid health program to directly negotiate drug prices with their makers — but only from 2026. It said that three companies, including GlaxoSmithKline, are poised to lower prices in January across at least 15 drugs.

Persons: —, Takeda, Biden Organizations: Service, Pfizer, Sanofi, Takeda Pharmaceutical, Reuters, Business, Biden, GlaxoSmithKline

[1/2] Mosquitoes are seen on stagnant water on the roadside during countrywide dengue infection, in Dhaka, Bangladesh, August 24, 2023. REUTERS/Mohammad Ponir Hossain/File Photo Acquire Licensing RightsCompanies Takeda Pharmaceutical Co Ltd FollowLONDON, Oct 6 (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Mohammad Ponir Hossain, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: REUTERS, Takeda Pharmaceutical, World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration, Thomson Locations: Dhaka, Bangladesh, United States, Europe, Africa, Asia, Latin America, Vietnam, Saharan Africa, EU

☆ Dengue Will 'Take Off' in Southern Europe, US, Africa This Decade, WHO Scientist Says
▼ + stars: | 2023-10-06 | by ( Oct. | At A.M. | ) www.usnews.com time to read: +4 min

By Jennifer RigbyLONDON (Reuters) - Dengue fever will become a major threat in the southern United States, southern Europe and new parts of Africa this decade, the WHO's chief scientist said, as warmer temperatures create the conditions for the mosquitoes carrying the infection to spread. Many cases go unrecorded, but in 2022 4.2 million cases were reported worldwide and public health officials have warned that near-record levels of transmission are expected this year. Earlier this week, the WHO recommended Takeda Pharmaceuticals' Qdenga vaccine for children aged 6 to 16 in areas where the infection is a significant public health problem. Qdenga is also approved by the EU regulator, but Takeda withdrew its application in the United States earlier this year, citing data collection issues. Dengue is spread by infected Aedes aegypti mosquitoes, which behave differently to the malaria-carrying kind.

Persons: Jennifer Rigby LONDON, ” Jeremy Farrar, ” Farrar, Farrar, ”, “, Takeda, Jennifer Rigby, Michele Gershberg, Sharon Singleton Organizations: World Health Organization, Reuters, Wellcome, WHO, Takeda Pharmaceuticals, U.S . Food, Drug Administration Locations: United States, Europe, Africa, Asia, Latin America, Bangladesh, Vietnam, Saharan Africa, EU

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

☆ Israeli cyber firm Legit Security raises $40 million in private funding
▼ + stars: | 2023-09-20 | by ( ) www.reuters.com time to read: +1 min

JERUSALEM, Sept 20 (Reuters) - Israeli cybersecurity firm Legit Security said on Wednesday it raised $40 million in a private funding round led by venture capital fund CRV. Since its founding in September 2020, Legit has raised a total of $77 million. It noted that its customer base includes brands such as Google, the NYSE, Kraft Heinz and Takeda Pharmaceuticals. On Tuesday, Israeli cyber firm Cato Networks said it raised $238 million in a late stage funding round, valuing the company at $3 billion. Israel has emerged as a global leader in cyber security in recent years.

Persons: TCV, Kraft Heinz, Takeda, Steven Scheer Organizations: Bessemer Venture Partners, Google, NYSE, Kraft, Takeda Pharmaceuticals, Cato Networks, Thomson Locations: CRV, Israel

☆ Japan's Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine
▼ + stars: | 2023-07-27 | by ( ) www.reuters.com time to read: +2 min

Companies Takeda Pharmaceutical Co Ltd FollowTOKYO, July 27 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) posted first-quarter profit that beat analysts' estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine. Operating profit rose 12% from a year earlier to 168.6 billion yen ($1.2 billion) in the three months through June 30, the drugmaker said. That compared with an average forecast of 150.7 billion yen from six analysts polled by Refinitiv. The company held its forecast for full-year operating profit at 349 billion yen. Analysts expect 481.1 billion yen on average for the year.

Persons: Takeda, Rocky Swift, Tom Hogue, Robert Birsel Organizations: Takeda Pharmaceutical, Refinitiv, Therapeutics, Shire Plc, Nikkei, Thomson Locations: Japan, United States, U.S

☆ Here are Thursday's biggest analyst calls: Credit Suisse, Amazon, Block, First Republic, FedEx & more
▼ + stars: | 2023-03-16 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: JPMorgan reiterates Amazon as overweight JPMorgan said growth deceleration concerns are overdone. Stifel upgrades FedEx to buy from hold Stifel said FedEx shares are compelling at current levels. JPMorgan reiterates Credit Suisse as overweight JPMorgan said it's standing by shares of the banking giant. JPMorgan upgrades Motorola Solutions to overweight from neutral JPMorgan called the telecom equipment company "high quality." Bank of America upgrades Takeda Pharmaceuticals to buy from neutral Bank of America said called Takeda a "stable value stock."

Takeda CFO Costa Saroukos in a 2018 picture. Mr. Saroukos joined Takeda in 2015 as CFO of Takeda’s European and Canadian operations before he was elevated to global CFO in 2018. WSJ: What did you learn from your deal-integration experiences that helped with the Takeda and Shire integration? ” — Costa Saroukos, CFO of TakedaAnother reason speed is important is to avoid losing talent. We broadened CFOinUrpocket to be used globally across 80 countries for the combined Takeda and Shire offices.

☆ New Dengue Vaccine Approved in Europe
▼ + stars: | 2022-12-08 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Takeda Pharmaceutical’s dengue vaccine, Qdenga, could generate peak annual sales of at least $700 million, the Tokyo-based company said. European health regulators cleared a new dengue vaccine from Takeda Pharmaceutical Co., a decision that could pave the way for its use around the world against the devastating mosquito-borne virus. The European Commission approved the two-dose shot in people ages 4 years and older, Takeda said Thursday.

☆ New U.S. cancer drug prices rise 53% in five years -report
▼ + stars: | 2022-11-02 | by ( Deena Beasley | ) www.reuters.com time to read: +4 min

"I do think there is a possibility we see launch prices go up," she said. Reuters GraphicsPorter, who championed inflation-based caps on drug prices, is calling for additional national legislation to link launch prices to how well a drug works. The report found that the average launch price of a self-administered cancer drug, after adjusting for inflation, rose by nearly 26% to $238,000 between 2017 and 2021. By 2022, six out of the eight newly-launched oral cancer drugs had prices over $200,000 per year. Based on current trends, the report calculated that by 2026, when Medicare will first be able to negotiate drug prices, the average self-administered cancer drug launch price will be nearly $325,000 per year and over $525,000 for pills and biologics.

☆ Bank of Japan’s stubbornness keeps yen volatile
▼ + stars: | 2022-09-22 | by ( ) www.reuters.com time to read: +2 min

Men look at an electric monitor displaying the Japanese yen exchange rate against the U.S. dollar and Nikkei share average in Tokyo, Japan September 14, 2022. read more That’s understandable, but it will make it harder to moderate an increasingly volatile exchange rate. The yen , currently trading around 144 per dollar, is at its weakest since 1998, but more important is the rate of change. A see-sawing foreign exchange rate, though, makes executives nervous. Exporters including carmakers Nissan Motor (7201.T) and Toyota Motor (7203.T), and drugmaker Takeda Pharmaceutical (4502.T), which reported nice forex tailwinds in its last quarterly report, are benefitting from unexpected exchange rate gains on paper.

Search resuls for: "Takeda Pharmaceutical"

15 mentions found